Monitored naltrexone without counseling for alcohol abuse/dependence in schizophrenia-spectrum disorders

Steven L. Batki, Jacqueline A. Dimmock, Michael Wade, Paul W. Gately, Martha Cornell, Stephen A. Maisto, Kate B. Carey, Robert Ploutz-Snyder

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


This clinical trial assessed the effects of monitored naltrexone treatment in 19 subjects with schizophrenia spectrum and alcohol use disorders in an eight-week prospective open pilot study. Naltrexone was directly administered to subjects in oral doses of 100 mg on Mondays and Wednesdays, and 150 mg on Fridays. Subjects received reimbursement for attending the three weekly study visits. Subjects continued to receive their usual psychiatric care with no added alcohol counseling provided. Alcohol use was assessed by self-report and biomarkers. Psychosis severity was measured by the Positive and Negative Syndrome Scale (PANSS). Subjects reported significant reductions in their number of drinks per week, drinks per drinking day, days of drinking to intoxication, and alcohol craving. Subjects also showed significant reductions in Addiction Severity Index (ASI) alcohol composite scores and in PANSS positive, negative and general psychopathology scores.

Original languageEnglish (US)
Pages (from-to)253-259
Number of pages7
JournalAmerican Journal on Addictions
Issue number4
StatePublished - Jul 2007

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Clinical Psychology
  • Psychiatry and Mental health


Dive into the research topics of 'Monitored naltrexone without counseling for alcohol abuse/dependence in schizophrenia-spectrum disorders'. Together they form a unique fingerprint.

Cite this